Almirall SA Reports Strong Q1 2025 Results with 15% Sales Growth and Robust EBITDA Increase
Almirall SA reports strong Q1 2025 results, with 15% year-over-year sales growth and 35% increase in EBITDA, driven by success in European Dermatology and biologics portfolio.
2 minutes to read